Summary
Girodazole, a new marine compound has been isolated from the sponge Pseudaxinyssa cantharella. Girodazole is active in vivo on several murine grafted tumors including leukemias (P388, L1210, i.p./i.p.) and solid tumors (MA 16/C mammary adenocarcinoma, M5076 histiocytosarcoma, s.c./i.v.). In addition, girodazole has identical cytotoxic properties in vitro on P388 and P388/DOX cells and retains antitumor activity in vivo on P388/DOX. Girodazole has a unique chemical structure different from those of known anticancer agents and of new compounds undergoing clinical trials. Biochemical studies indicate that girodazole inhibits protein synthesis during the elongation/termination steps. Toxicological studies have been done in mice and in dogs and did not reveal any major toxic effect which could preclude administration in patients. Girodazole is now undergoing phase I clinical studies.
Similar content being viewed by others
References
Rinehart KL, Shaw PD, Shield LS, Gloer JB, Harbour GC, Koker MES, Samain D, Schwartz RE, Tymiak AA, Weller DL, Carter GT, Munrom HG, Hughes RG, Renis HE, Swynenberg EB, Stringfellow DA, Vavra JJ, Coats JH, Zurenko GE, Kuentzel SL, Li LH, Bakus GJ, Brusca RC, Craft LL, Young DN, Connor JL. Marine natural products as sources of antiviral, antimicrobial and antineoplastic agents. Pure Appl Chem 53: 795–817, 1981
Bergmann W, Feeney RJ. Contributions to the study of marine products. XXXII. The nucleosides of sponges. J Org Chem 16: 981–987, 1951
Rinehart KL, Gloer JB, Wilson GR, Hughes RG, Li LH, Renis HE, McGovren JP. Antiviral and antitumor compounds from tunicates. Fed Proc 42: 87–90, 1983
Chun HG, Davies B, Hoth D, Suffness M, Plowman J, Flora K, Grieshaber C, Leyland-Jones B. Didemnin B: The first marine compound entering clinical trials as an antineoplastic agent. Investigational New Drugs 4: 279–284, 1986
Burres NS, Clement JJ. Antitumor activity and mechanism of action of the novel marine natural products Mycalamide -A and-B and Onnamide. Cancer Res 49: 2935–2940, 1989
Burres NS, Sazesh S, Gunawardana GP, Clement JJ. Antitumor activity and nucleic acid binding properties of Dercitin, a new acridine alkaloid isolated from a marine dercitus species sponge. Cancer Res 49: 5267–5274, 1989
Pettit GR, Kamano Y, Brown P, Gust D, Inoue M, Herald CL. Structure of the cyclic peptide dolastatin 3 from Dolabella auricularia. J Am Chem Soc 104: 905–907, 1982
Pettit GR, Herald CL, Doubek DL, Herald DL. Isolation and structure of bryostatin 1. J Am Chem Soc 104: 6846–6848, 1982
Ahond A, Bedoya Zurita M, Colin M, Fizames C, Laboute P, Lavelle F, Laurent D, Poupat C, Pusset J, Pusset M, Thoison O, Potier P. La girolline, nouvelle substance antitumorale extraite de l'éponge Pseudaxinyssa cantharella. CR Acad Sci Paris 307 (II): 145–148, 1988
Johnson RK, Chitnis MP, Embrey WM, Gregory EB. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62: 1535–1547, 1978
Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep, part 3: 1–103, 1972
Gookin RMC. Methods in Molecular Biology: Nucleic-Acids. Humana Press, 1984
Zucker WV, Schulman HM. Stimulation of globin chain initiation by hemin in the reticulocyte cell free system. Proc Natl Acad Sci USA 59: 582–589, 1968
Jackson RJ, Hunt, T. Preparation and use of nuclease-treated rabbitreticulocyte lysates for the translation of eukaryotic messenger RNA. Methods in Enzymology 96: 50–74, 1983
Pelham HRB, Jackson RJ. An efficient mRNA-dependent translation system from reticulocyte lysates. Eur J Biochem 67: 247–256, 1976
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685, 1970
Schabel FM, Griswold DP, Laster WR. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1: 411–435, 1977
Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62: 1471–1488, 1978
Talmadge JE, Key ME, Hart IR. Characterization of a murine ovarian-reticulum cell sarcoma of histiocytic origin. Cancer Res 41: 1271–1280, 1981
Langdon SP, Gescher A, Hickman JA, Stevens MFG. The chemosensitivity of a new experimental model — the M5076 reticulum cell sarcoma. Eur J Cancer Clin Oncol 20: 699–705, 1984
Nicolson GL. Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells. Biochim. Biophys Acta 695: 113–176, 1982
Moldave K. Eukaryotic protein synthesis Ann Rev. Biochem 54: 1109–1149, 1985
Corbett TH, Valeriote FA, Baker LH. Is the P388 murine tumor no longer adequate as a drug discovery model? Investigational New Drugs 5: 3–20, 1987
Atassi G. Do we need new chemosensitive experimental models? Eur J Cancer Clin Oncol 20: 699–705, 1980
Bissery MC, Bayssas M, Lavelle F. Solid tumor activity of RP 49532, a marine antitumor agent (Abstract). Proc Am Assoc Cancer Res 30: 580, 1989
Lavelle F, Fizames C, Ahond A, Poupat C, Curaudeau A. Experimental properties of RP 49532, a new antitumor marine compound (Abstract). Proc Am Assoc Cancer Res 30: 583, 1989
Staquet MJ, Byar DP, Green SB, Rozencweig M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep 67: 753–765, 1983
Armand JP, Herrera A. Interface pre-clinique-Phase I des nouvelles molécules en cancérologie. In: Strauch G, Spriet A (eds) Pharmacologie Clinique: Actualités et Perspectives. Les Editions INSERM (Vol. 156), Paris, pp. 195–206, 1987
Montgomery JA, Johnston TP, Shealy YF. Drugs for neoplastic diseases. In: Burger A (ed) Medicinal Chemistry. Wiley-Interscience, New York, 1970, Third Edition, Part I, pp 680–783
Uehara Y, Hori M, Umezawa H. Negamycin inhibits termination of protein synthesis directed by phage f 2 RNA in vitro. Biochim. Biophys. Acta 374: 82–95, 1974
Vrijsen R, Vanden Berghe DA, Vlietinck AJ, Boeye A. Lycorine: an eukaryotic termination inhibitor? J Biol Chem 261: 505–507, 1986
Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11: 511–519, 1975
Dawkins AW. Phytotoxic compounds produced by Fusarium equiseti. II. The chemistry of diacetoxyscirpenol. J Chem Soc (C): 116–123, 1966
Kupchan SM, Britton RW, Ziegler MF, Sigel CW. Bruceantin, a new potent antileukemic simaroubolide from Brucea antidysenterica. J Org Chem 38: 178–179, 1973
Ottenheijm HCJ, Van der Broek LAGM. The development of sparsomycin as an anti-tumor drug. Anti-Cancer Drug Design 2: 333–337, 1988
Arseneau JC, Wolter JM, Kuperminc M, Ruckdeschel JC. A phase II study of bruceantin (NSC-165, 563) in advanced malignant melanoma. Investigational New Drugs 1: 239–242, 1983
Adler SS, Lowenbraun S, Birch B, Jarrell R, Garrard J. Anguidine: a broad phase II study of the Southeastern Cancer Study Group. Cancer Treat Rep 68: 423–425, 1984
Liao LL, Kupchan SM, Horwitz SB. Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol Pharmacol 12: 167–176, 1976
Liao LL, Grollman AP, Horwitz SB Mechanism of action of the 12, 13-epoxy trichothecene anguidine, an inhibitor of protein synthesis. Biochim Biophys Acta 454: 273–284, 1976
Schabel FM, Skipper HE, Trader MW, Laster WM, Griswold DP, Corbett TH. Establishment of crossresistance profiles for new agents. Cancer Treat Rep 67: 905–922, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lavelle, F., Zerial, A., Fizames, C. et al. Antitumor activity and mechanism of action of the marine compound girodazole. Invest New Drugs 9, 233–244 (1991). https://doi.org/10.1007/BF00176976
Issue Date:
DOI: https://doi.org/10.1007/BF00176976